Galecto Inc (GLTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galecto Inc (GLTO) has a cash flow conversion efficiency ratio of -0.040x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.60 Million) by net assets ($510.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Galecto Inc (GLTO) net asset quality to measure how much of total assets are equity-financed.
Galecto Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Galecto Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GLTO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Galecto Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galecto Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Andeli Department Store Co Ltd
SHG:603031
|
0.085x |
|
La-Z-Boy Incorporated
NYSE:LZB
|
0.085x |
|
Inox Wind Limited
NSE:INOXWIND
|
-0.058x |
|
Shanghai Bright Power Semiconductor
SHG:688368
|
0.045x |
|
American Bitcoin Corp
NASDAQ:ABTC
|
-0.061x |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
-0.020x |
|
Chongqing Iron & Steel Co Ltd Class A
SHG:601005
|
0.058x |
|
Deutsche EuroShop AG
F:DEQ
|
0.014x |
Annual Cash Flow Conversion Efficiency for Galecto Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Galecto Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Galecto Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $240.38 Million | $-6.73 Million | -0.028x | +97.62% |
| 2024-12-31 | $15.83 Million | $-18.62 Million | -1.176x | -3.04% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more